What is the role of consistency in Emerging Markets

Aubrey Capital argues that quality growth stocks in emerging markets have outperformed the MSCI Emerging Markets Index over the long run, but returns have been uneven and recently lagged due to India weakness, China slowdown and elevated valuations. The article highlights strong compounding fundamentals at companies such as TSMC, CATL, Eicher Motors and Varun Beverages, emphasizing high ROE, cash generation and earnings growth, though dilution and competition remain key risks. Overall, the piece is a thematic market commentary rather than a catalyst-driven event.

Analysis

The market is treating “quality EM” like a style factor, but the better framing is balance-sheet optionality. Companies that fund growth internally can keep compounding through funding shocks and FX stress, while levered growers get forced into value-destructive refinancing exactly when local rates or capital markets tighten. That creates a hidden winner set in EM: firms with net cash and pricing power can buy back share of market during downturns, while aggressive competitors are forced to retrench.

TSM remains the cleanest expression of that dynamic because its competitive moat is not just process leadership, but capital allocation discipline. The second-order effect is that foundry concentration keeps rising as weaker peers struggle to fund node transitions, so the cycle may look cyclical in revenue but secular in share. The main risk is not demand normalization; it is policy or geopolitics compressing the valuation multiple before fundamentals roll over, which can happen over weeks rather than years.

The underappreciated contrarian point is that recent underperformance may be setting up a better forward IRR, not invalidating the factor. When high-quality EM names de-rate while earnings and cash conversion remain intact, future returns usually improve once macro uncertainty fades—especially if India stabilizes and China stops dragging the benchmark. The better trade is not “buy EM beta,” but own the compounding businesses and avoid capital-intensive pseudo-growth where reported earnings outpace per-share value creation.

Key Decisions for Investors

• Add to TSM on any 5-8% pullback over the next 2-6 weeks; target a 12-month hold. Risk/reward favors a 15-20% upside move if the market re-rates quality growth, with downside limited by balance-sheet strength and structural foundry share gains.
• Use TSM as the long leg in a pair versus a weaker, more capital-intensive semiconductor or hardware supplier over 3-9 months. The thesis is that capital intensity will increasingly separate winners from strugglers as the cycle turns, offering cleaner EPS durability on the long side.
• Prefer cash-generative, net-cash EM compounders over broad EM index exposure for the next 6-12 months. The index still carries macro and dilution baggage that can cap upside even if fundamentals improve.
• If macro volatility spikes, sell downside puts rather than owning outright beta in quality EM names. That structure monetizes elevated implied vol while preserving upside to a rerating in the next 1-2 quarters.
• Avoid initiating new longs in high-return but newly contested domestic EM consumer franchises where competition can force normalization of returns. The risk/reward is inferior because market share defense often requires reinvestment before earnings growth stabilizes.